TSPO ligands prevent the proliferation of vascular smooth muscle cells and attenuate neointima formation through AMPK activation
- 12 September 2019
- journal article
- research article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 41 (1) , 34-46
Abstract
Abnormal growth of the intimal layer of blood vessels (neointima formation) contributes to the progression of atherosclerosis and in-stent restenosis. Recent evidence shows that the 18-kDa translocator protein (TSPO), a mitochondrial membrane protein, is involved in diverse cardiovascular diseases. In this study we investigated the role of endogenous TSPO in neointima formation after angioplasty in vitro and in vivo. We established a vascular injury model in vitro by using platelet-derived growth factor-BB (PDGF-BB) to stimulate rat thoracic aortic smooth muscle cells (A10 cells). We found that treatment with PDGF-BB (1-20 ng/mL) dose-dependently increased TSPO expression in A10 cells, which was blocked in the presence of PKC inhibitor or MAPK inhibitor. Overexpression of TSPO significantly promoted the proliferation and migration in A10 cells, whereas downregulation of TSPO expression by siRNA or treatment with TSPO ligands PK11195 or Ro5-4864 (104 nM) produced the opposite effects. Furthermore, we found that PK11195 (10-104 nM) dose-dependently activated AMPK in A10 cells. PK11195-induced inhibition on the proliferation and migration of PDGF-BB-treated A10 cells were abolished by compound C (an AMPK-specific inhibitor, 103 nM). In rats with balloon-injured carotid arteries, TSPO expression was markedly upregulated in the carotid arteries. Administration of PK11195 (3 mg/kg every 3 days, ip), starting from the initial balloon injury and lasting for 2 weeks, greatly attenuated carotid neointima formation by suppressing balloon injury-induced phenotype switching of VSMCs (increased α-SMA expression). These results suggest that TSPO is a vascular injury-response molecule that promotes VSMC proliferation and migration and is responsible for the neointima formation after vascular injury, which provides a novel therapeutic target for various cardiovascular diseases including atherosclerosis and restenosis.Keywords
This publication has 36 references indexed in Scilit:
- A role for TSPO in mitochondrial Ca2+ homeostasis and redox stress signalingCell Death & Disease, 2017
- Translocator Protein (TSPO) Role in Aging and Alzheimer’s DiseaseCurrent Aging Science, 2015
- The Mitochondrial Translocator Protein, TSPO, Inhibits HIV-1 Envelope Glycoprotein Biosynthesis via the Endoplasmic Reticulum-Associated Protein Degradation PathwayJournal of Virology, 2014
- MicroRNA-663 Regulates Human Vascular Smooth Muscle Cell Phenotypic Switch and Vascular Neointimal FormationCirculation Research, 2013
- The translocator protein (TSPO) ligand PK11195 induces apoptosis and cell cycle arrest and sensitizes to chemotherapy treatment in pre- and post-relapse neuroblastoma cell linesCancer Biology & Therapy, 2013
- Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disordersNature Reviews Drug Discovery, 2010
- Role of Smooth Muscle Cells in the Initiation and Early Progression of AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Translocator protein 18 kDa (TSPO): Molecular sensor of brain injury and repairPharmacology & Therapeutics, 2008
- Molecular Regulation of Vascular Smooth Muscle Cell Differentiation in Development and DiseasePhysiological Reviews, 2004
- Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategiesNature Medicine, 2002